Australia - English - Department of Health (Therapeutic Goods Administration)

marine blue australia pty ltd - 4-methylbenzylidene camphor,butyl methoxydibenzoylmethane,octocrylene,zinc oxide -

Australia - English - Department of Health (Therapeutic Goods Administration)

marine blue australia pty ltd - homosalate, quantity: 100 mg/g; octyl salicylate, quantity: 50 mg/g; butyl methoxydibenzoylmethane, quantity: 35 mg/g; octocrylene, quantity: 50 mg/g; 4-methylbenzylidene camphor, quantity: 30 mg/g - lotion - excipient ingredients: trolamine; purified water; methyl hydroxybenzoate; butyl hydroxybenzoate; dl-alpha-tocopheryl acetate; aloe vera; phenoxyethanol; propyl hydroxybenzoate; carbomer 941; xanthan gum; stearic acid; silicon dioxide; edetate sodium; pvp/eicosene copolymer; cetostearyl alcohol; polyglyceryl-3 diisostearate; acrylates/c10-30 alkyl acrylate crosspolymer - may assist in preventing some skin cancers (sunscreen) ; may reduce the risk of some skin cancers (sunscreen) ; spf 50 plus broad spectrum very high protection sunscreen ; can aid in the prevention of premature skin ageing (sunscreen) ; can aid in the prevention of solar keratosis (sunscreen) ; can aid in the prevention of sunspots (sunscreen)

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

kenso corporation (m) sdn. bhd. - trifluralin; liquid hydrocarbon - emulsifiable concentrate - trifluralin anilide/aniline-dinitro active 480.0 g/l; liquid hydrocarbon solvent other 475.0 g/l - herbicide - adzuki bean | annual medic seed crop | barley | barley - prior to sowing | barley - prior to sowing & incorporated | barley pre& - amaranth or amaranthus | amsinckia,yellow burrweed or burr grass | annual broadleaf weed | annual grass weed | annual phalaris | annual ryegrass | annual ryegrass - seed | annual ryegrass - suppression | barley grass | barnyard grass or water grass | barnyard or water grass | barnyard or water grass - seed | brome grass | brome grass - suppression | button grass | caltrop or yellow vine | caltrop or yellow vine - seed | caltrop or yellow vine - suppression | canary grass | capeweed | cereal oat | cereal oats - suppression | climbing buckwheat - suppression | columbus grass - seed | common fumitory | corn gromwell, ironweed or sheepweed | crowsfoot grass | deadnettle | deadnettle - suppression | doublegee - suppression | fumitory | fumitory - red | fumitory - seed | fumitory - suppression | fumitory - white | geranium | giant or black pigweed | guinea grass - seed | iceplant - suppression | indian hedge mustard | innocent weed or grass | ivy leaf speedwell | johnson grass - seed | liverseed grass - seed | love

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - yellow fever virus, quantity: 1000 pfu e.1000 mouse ld50 - injection, powder for - excipient ingredients: calcium chloride dihydrate; magnesium sulfate heptahydrate; histidine hydrochloride; sodium chloride; dibasic sodium phosphate dihydrate; alanine; sorbitol; potassium chloride; lactose monohydrate; monobasic potassium phosphate; sodium hydroxide - prevention of yellow fever. vaccination is recommended for:,? every individual aged 9 months and over living or travelling through an endemic area with a current or periodic risk of yellow fever transmission. ? non-vaccinated individual moving from an endemic area with a current or periodic risk of yellow fever transmission to a potentially receptive non-endemic area with a current or periodic risk of yellow fever transmission. ? laboratory workers handling potentially infectious materials. in order to be officially recognised, the yellow fever vaccination must be administered in an approved vaccination centre and registered on an international certificate. the validity period of the certificate is established according to international health regulations recommendations and starts 10 days after primary vaccination and immediately after re-vaccination.

Australia - English - Department of Health (Therapeutic Goods Administration)

universal pharmaceuticals pty ltd - shark-liver oil, quantity: 200 mg (equivalent: colecalciferol, qty 500 ng; equivalent: vitamin a, qty 18 re); euphausia superba oil, quantity: 100 mg (equivalent: eicosapentaenoic acid, qty 10.8 mg; equivalent: docosahexaenoic acid, qty 5.85 mg); natural fish oil, quantity: 150 mg (equivalent: docosahexaenoic acid, qty 18 mg; equivalent: eicosapentaenoic acid, qty 27 mg); cod-liver oil, quantity: 150 mg (equivalent: vitamin a, qty 54 re; equivalent: colecalciferol, qty 375 ng) - capsule, soft - excipient ingredients: soya oil; d-alpha-tocopherol; purified water; glycerol; gelatin - maintain/support general health and wellbeing ; maintain/support (state vitamin/mineral/nutrient) levels in the body

United States - English - NLM (National Library of Medicine)

abbvie inc. - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol 2.5 mg - marinol is indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. marinol is contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)] . marinol, a synthetic cannabinoid, may cause fetal harm. avoid use of marinol in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations] . cannabinoids have been found in the umbilical cord blood from pregnant women who s

United States - English - NLM (National Library of Medicine)

thepharmanetwork, llc - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - marinol is indicated in adults for the treatment of: • anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). • nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. marinol® (dronabinol capsules, usp) is contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)] . risk summary marinol, a synthetic cannabinoid, may cause fetal harm. avoid use of marinol in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations]. cannabinoids have been found

United States - English - NLM (National Library of Medicine)

thepharmanetwork, llc - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - marinol is indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.  marinol® (dronabinol capsules, usp), is contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)].  risk summary marinol, a synthetic cannabinoid, may cause fetal harm. avoid use of marinol in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes (see clinical considerations). cannabinoids have been found i

Australia - English - Department of Health (Therapeutic Goods Administration)

marine blue australia pty ltd - butyl methoxydibenzoylmethane,homosalate,octocrylene,octyl salicylate,octyl triazone -

Australia - English - Department of Health (Therapeutic Goods Administration)

marine blue australia pty ltd - butyl methoxydibenzoylmethane,homosalate,octocrylene,octyl salicylate,oxybenzone -